Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets

Acta Gastro-Enterologica Belgica

Volumn 63, Issue 2, 2000, Pages 210-212

  Hong, Z ^a   Standring, D N ^a   Baroudy, B ^a   Lau, J Y N ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti HCV; HCV; Helicase; IFN; Polymerase; Protease; Ribavirin

Indexed keywords

ALPHA INTERFERON; ENZYME INHIBITOR; HELICASE; REBETRON; RNA DIRECTED RNA POLYMERASE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; VIRUS ENZYME;

CONFERENCE PAPER; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; VIRUS GENE; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA HELICASES; DNA, COMPLEMENTARY; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; PROTEASE INHIBITORS; SENSITIVITY AND SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0033917757     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. CHOO Q.L., KUO G., WEINER A.J., OVERBY L.R., BRADLEY D.W., HOUGHTON M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 1989, 244 : 59-362.
2. KUO G., CHOO Q.L., ALTER H.J., GITNICK G.L., REDEKER A.G., PURCELL R.H., MIYAMURA T., DIENSTAG J.L., ALTER M.J., STEVENS C.E., TEGTMEIER G.E., BONINO F., COLOMBO M., LEE S., KUO C., BERGER K., SHUSTER J.R., OVERBY L.R., BRADLEY D.W., HOUGHTON M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B-hepatitis. Science, 1989, 244 : 362-364.
3. DAVIS G.L., BALART L.A., SCHIFF E.R., LINDSAY K., BODENHEIMER H.C. JR, PERRILLO R.P., CAREY W., JACOBSON I.M., PAYNE J., DIENSTAG J.L. et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med., 1989, 321 : 1501-6.
4. MCHUTCHISON J.G., GORDON S.C., SCHIFF E.R., SHIFFMAN M.L., LEE W.M., RUSTGI V.K., GOODMAN Z.D., LING M.H., CORT S., ALBRECHT J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med., 1998, 339 : 1485-92.
5. POYNARD T., MARCELLIN P., LEE S.S., NIEDERAU C., MINUK G.S., IDEO G., BAIN V. HEATHCOTE J., ZEUZEM S. TREPO C., ALBRECHT J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 1998, 352 : 1426-32.
6. DAVIS G.L., ESTEBAN-MUR R., RUSTGI V., HOEFS J., GORDON S.C., TREPO C., SHIFFMAN M.L., ZEUZEM S., CRAXI A., LING M.H. ALBRECHT J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med., 1998, 339 : 1493-9.
7. GRAKOUI A., MCCOURT D.W., WYCHOWSKI C., FEINSTONE S.M., RICÉ C.M. Characterization of the hepatitis C virus-encoded serine protease : determination of proteinase-dependent polyprotein cleavage. J. Virol. 1993, 67 : 2832-2843.
8. BARTENSCHLAGER R., RHLBORN-LAAKE L., MOUS J., JACOBSON H. Kinetics and structural analysis of hepatitis C virus polyprotein processing. J. Virol., 1994, 68 : 5045-5055.
9. SATOH S., TANJI Y., HIJIKATA M., KIMURA K., SHIMOTOHNO K. The N-terminal region of hepatitis C virus non-structural protein (NS3) is essential for stable complex formation with NS4A. J. Virol., 1995, 69 : 4255-4260.
10. KIM J.L., MORGENSTERN K.A., LIN C., FOX T., DWYER M.D., LANDRO J.A., CHAMBERS S.P., MARKLAND W., LEPRE C.A., O'MALLEY E.T., HARBESON S.L., RICE C.M., MURCKO M.A., CARON P.R., THOMSON J.A. Cryystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell, 1996, 87 : 343-355.
11. TAI C.L., CHI W.K., CHEN D.S., HWANG L.H. The helicase acclivity associated with hepatitis C virus non-structural protein 3 (NS3). J. Virol., 1996, 70 : 8477-8484.
12. YAO N., HESSON T., CABLE M., HONG Z., KWONG A.D., LE H.V., WEBER P.C. Structure of the hepatitis C virus RNA helicase domain. Nat. Struct. Biol., 1997, 4 : 463-7.
13. BEHRENS S.E., TOMEI L., DE FRANCESCO R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J., 1996, 15 : 12-22.
14. LOHMANN V., KORNER F., HERIAN U., BARTENSCHLAGER R. Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification ot amino acid sequence motifs essential for enzymatic activity. J. Virol., 1997, 71 : 8416-28.
15. FERRARI E., WRIGHT-MINOGUE J., FANG J.W., BAROUDY B.M., LAU J.Y., HONG Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol., 1999, 73 : 1649-54.
16. LEESBURG C.A., CABLE M.B., FERRARI E., HONG Z., MANNARION A.F., WEBER P.C. Crystal structure of the RNA-dependent RNA plymrease from hepatitis C virus reveals a fully encircled active site. Nature Structural Biology, 1999, 10 : 937-943.